Streetbeat News

Price Targets

RCM

Barclays analyst Stephanie Davis has initiated coverage on R1 RCM (NASDAQ:RCM) with an Overweight rating and set a price target of $14. This new coverage could influence investor sentiment and potentially impact R1 RCM's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:36 am

TALK

Barclays analyst Stephanie Davis has initiated coverage on Talkspace (NASDAQ:TALK) with an Equal-Weight rating and set a price target of $2.5 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:35 am

MDRX

Barclays analyst Stephanie Davis has initiated coverage on Veradigm (NASDAQ:MDRX) with an Equal-Weight rating and set a price target of $11 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:32 am

COR

Barclays analyst Stephanie Davis has initiated coverage on Cencora (NYSE:COR) with an Overweight rating and set a price target of $242.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:25 am

PNC

Keefe, Bruyette & Woods analyst David Konrad has maintained an Underperform rating on PNC Financial Services Group (NYSE:PNC) but increased the price target from $125 to $145.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:24 am

CAH

Barclays analyst Stephanie Davis has initiated coverage on Cardinal Health (NYSE:CAH) with an Overweight rating and set a price target of $117.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:23 am

KEY

Keefe, Bruyette & Woods analyst David Konrad has maintained an Outperform rating on KeyCorp (NYSE:KEY) and increased the price target from $15 to $17.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:21 am

AMLX

Baird analyst Joel Beatty has initiated coverage on Amylyx Pharmaceuticals with an Outperform rating and set a price target of $37 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:15 am

JAZZ

Baird analyst Joel Beatty has initiated coverage on Jazz Pharmaceuticals with an Outperform rating and set a price target of $160. This new coverage could influence investor sentiment and potentially impact the stock's performance in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:13 am

ITCI

Baird analyst Joel Beatty has initiated coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with an Outperform rating and set a price target of $83.

Portfolio Pulse from Benzinga Newsdesk

January 03, 2024 | 10:11 am